输血依赖型较低危组骨髓增生异常综合征的治疗进展  

Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes

作　　者：冯悦 罗兴春 朱玉 刘蓓[2] FENG Yue;LUO Xingchun;ZHU Yu;LIU Bei(The First Clinical Medical College of Lanzhou University,Lanzhou 730000,China;Department of Hematology,The First Hospital of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第一临床医学院,兰州730000 [2]兰州大学第一医院血液科,兰州730000

出　　处：《肿瘤防治研究》2021年第4期409-413,共5页Cancer Research on Prevention and Treatment

摘　　要：目前输血依赖型较低危组骨髓增生异常综合征(LR-MDS)患者在促红细胞生成剂治疗无效或复发后的治疗选择有限。MDS的病理学和分子遗传学研究推进了MDS精准化治疗的发展,小分子抑制剂如转化生长因子β抑制剂、端粒酶抑制剂、低氧诱导因子脯氨酰羟化酶抑制剂等为患者提供了新的治疗方案。本文综述了输血依赖型LR-MDS患者的治疗,并着重讨论了新的靶向药物的最新临床研究及进展。At present,the patients with transfusion-dependent lower-risk myelodysplastic syndromes(MDS)have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed.With more understanding of the pathological and molecular genetics characteristics of MDS,the development of precise medical treatment of MDS has been promoted.Small-molecule inhibitors,such as transforming growth factorβinhibiter,telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor,provide novel therapeutic strategies for patients.This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents.

关 键 词：输血依赖 较低危组骨髓增生异常综合征 小分子抑制剂 

分 类 号：R733.3[医药卫生—肿瘤]